Search Result

Results for "

Analgesic effect

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Adenosine Receptor (2) Adrenergic Receptor (8) Akt (1) Amino Acid Derivatives (1) Aminopeptidase (1) AMPK (2) Antibiotic (2) Apoptosis (6) ATP Synthase (1) Autophagy (1) Bacterial (4) Biochemical Assay Reagents (1) Calcium Channel (6) Cannabinoid Receptor (2) Carbonic Anhydrase (2) Caspase (1) CCR (1) Cholinesterase (ChE) (1) COX (18) Cytochrome P450 (3) Dengue Virus (1) Dopamine Receptor (1) Dopamine Transporter (4) Drug Derivative (6) Drug Intermediate (1) Drug Metabolite (3) E1/E2/E3 Enzyme (1) Endogenous Metabolite (6) Epoxide Hydrolase (1) ERK (2) Fungal (1) GABA Receptor (6) GLUT (1) Guanylate Cyclase (1) HCV (1) HIF/HIF Prolyl-Hydroxylase (2) Histamine Receptor (4) Imidazoline Receptor (3) Insecticide (1) Interleukin Related (9) Isotope-Labeled Compounds (9) JAK (1) Leukotriene Receptor (2) LOX-1 (2) mAChR (5) Mas-related G-protein-coupled Receptor (MRGPR) (2) mGluR (2) Monoamine Oxidase (3) mTOR (1) Na+/K+ ATPase (1) nAChR (5) NF-κB (5) NO Synthase (1) Opioid Receptor (36) P2X Receptor (1) Parasite (1) PGE synthase (1) PI3K (1) Platelet-activating Factor Receptor (PAFR) (1) Polo-like Kinase (PLK) (1) Potassium Channel (9) Reference Standards (14) ROCK (2) Serotonin Transporter (5) Sigma Receptor (1) Sodium Channel (9) STAT (1) Taste Receptor (1) Thyroid Hormone Receptor (2) TNF Receptor (7) Trk Receptor (6) TRP Channel (7) UGT (1) URAT1 (1) VEGFR (1)
By Research Areas:	Cancer (17) Cardiovascular Disease (7) Endocrinology (6) Infection (8) Inflammation/Immunology (63) Metabolic Disease (7) Neurological Disease (104)
Click Chemistry:	Azide (2)

141

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0509A

Amikacin Maximum Cited Publications 26 Publications Verification BAY 41-6551	Bacterial Antibiotic	Infection Cancer
Amikacin (BAY 41-6551) is a semisynthetic kanamycin analog that is active against most Gram-negative bacteria, including gentamicin- and tobramycin-resistant strains. Significant inhibitory effect. Amikacin is ototoxic and nephrotoxic. Amikacin can be used in bacteriostatic, anti-cancer and analgesic studies .

HY-P0210

DAMGO Maximum Cited Publications 12 Publications Verification	Opioid Receptor	Cancer
DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a K_d of 3.46 nM for native μ-OPR .

HY-108449

Acoltremon 2 Publications Verification WS-12; AR-15512; AVX-012	TRP Channel	Neurological Disease
Acoltremon (WS-12; AR-15512) is a potent and selective TRPM8 agonist, the menthol derivative, as a cooling agent. Acoltremon shows analgesic effect, and can be used in chronic neuropathic pain research .

HY-B0363

Nimesulide 5+ Cited Publications R805	COX	Inflammation/Immunology Cancer
Nimesulide is a selective COX-2 inhibitor, with IC₅₀s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC₅₀ >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.

HY-B0985

Phenazopyridine hydrochloride 2 Publications Verification	TRP Channel	Neurological Disease
Phenazopyridine hydrochlorideis a competitive SARM1 inhibitor, with IC₅₀ 145 μM. Phenazopyridine hydrochlorideis a TRPM8 antagonist. Phenazopyridine hydrochloride has a local anesthetic/analgesic effect. Phenazopyridine hydrochlorideis used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine hydrochloridecan promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases .

HY-13913

NS-398 15+ Cited Publications	COX	Inflammation/Immunology Cancer
NS-398 is a non-steroidal an-inflammatory agent with analgesic and antipyretic effects, and selectively inhibits prostaglandin G/H synthase 2/cyclooxygenase 2 (COX-2) activity, with an IC₅₀ of 3.8 μM, and has no effect on COX-1 at 100 μM.

HY-N3017

Artemitin 1 Publications Verification	Antibiotic	Neurological Disease Inflammation/Immunology
Artemitin is a flavonoid neuroanesthetic agent with moderate cytotoxicity. Artemitint has selective inhibitory activity against Meth-A sarcoma cells with an ED₅₀ of 5-10 μg/mL, and has no significant effect on LLC lung cancer cells. Artemitin exerts anticancer activity by affecting cell proliferation signaling pathways, and also has potential anti-inflammatory and neuroprotective effects. Artemitin exhibits a dose-dependent antinociceptive effect in the mouse hot plate test, with an ED₅₀ of 1.6 μg/kg, and has analgesic activity .

HY-N8290

Lactupicrin Lactucopicrin	LOX-1 NF-κB Cholinesterase (ChE) Parasite	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
Lactupicrin (Lactucopicrin) exhibits analgesic, sedative, antimalarial activities and atheroprotective effect. Lactupicrin inhibits acetylcholinesterase (AChE) with an IC₅₀ of 150.3 μM. Lactupicrin is an orally active characteristic bitter sesquiterpene lactone .

HY-N8487

7-Methoxyflavone	Cytochrome P450	Neurological Disease Inflammation/Immunology Cancer
7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .

HY-P3445A

Anrikefon acetate HSK21542 acetate	Opioid Receptor	Neurological Disease
Anrikefon (HSK21542) acetate is a kappa opioid receptor agonist with analgesic effect .

HY-W013331

Deoxyartemisinin 1 Publications Verification 2-Deoxyartemisinin	TNF Receptor	Neurological Disease Inflammation/Immunology
Deoxyartemisinin (2-Deoxyartemisinin) is an orally active anti-inflammatory and analgesic agent. Deoxyartemisinin selectively reduces the level of the pro-inflammatory cytokine TNF-α. Deoxyartemisinin alleviates neuropathic pain, inflammatory pain, and croton oil-induced ear edema.\nDeoxyartemisinin exerts an analgesic effect against thermal stimulation. Deoxyartemisinin has anti-ulcer activity. Deoxyartemisinin can be used in research related to inflammatory diseases, pain, and gastric ulcers .

HY-17391

Pamabrom	Adenosine Receptor	Endocrinology
Pamabrom is a diuretic that acts on the opioid receptor-nitric oxide (NO) -cyclic guanosine monophosphate (cGMP) -K ⁺ channel pathway. Pamabrom exerts peripheral antinociceptive activity by activating this pathway. The mechanism involves activating opioid receptors, promoting the release of nitric oxide, and then influencing cyclic guanosine monophosphate and K channels to produce an analgesic effect. Pamabrom is orally active and is mainly used in the research and treatment of premenstrual syndrome and primary dysmenorrhea[1].

HY-P3445

Anrikefon HSK21542	Opioid Receptor	Neurological Disease
Anrikefon (HSK21542) is a kappa opioid receptor agonist with analgesic effect .

HY-P0210B

DAMGO TFA Maximum Cited Publications 12 Publications Verification	Opioid Receptor	Cancer
DAMGO TFA is a μ-opioid receptor (μ-OPR ) selective agonist with a K_d of 3.46 nM for native μ-OPR .

HY-N0398

Sec-O-Glucosylhamaudol	Opioid Receptor	Neurological Disease
Sec-O-Glucosylhamaudol is a natural compound extracted from Peucedanum japonicum Thunb, decreases levels of μ-opioid receptor, with analgesic effect .

HY-109054A

O-Desmethyltramadol hydrochloride	Drug Metabolite Opioid Receptor	Neurological Disease
O-Desmethyltramadol hydrochloride is the main active metabolite of tramadol (Tramadol) and can cross the blood-brain barrier. O-Desmethyltramadol hydrochloride mainly exerts its analgesic effect by activating the µ-opioid receptor (µ-OR) .

HY-W176629

Hydrocotarnine 1 Publications Verification	E1/E2/E3 Enzyme Interleukin Related	Neurological Disease Metabolic Disease Inflammation/Immunology
Hydrocotarnine is a Cbl inhibitor, and results in inflammasome-mediated IL-18 secretion in colitis. Hydrocotarnine increases expression of GLUT1 and cellular glucose uptake in glycolytic metabolism. Hydrocotarnine acts as an agent that provides analgesic effect in cancer research .

HY-137451

Sivopixant 1 Publications Verification S-600918	P2X Receptor	Neurological Disease
Sivopixant (S-600918) is a potent and selective P2X3 receptor antagonist (P2X3 IC₅₀=4.2 nM; P2X2/3 IC₅₀=1100 nM). Sivopixant shows strong analgesic effect .

HY-W013712

GI-530159	Potassium Channel	Neurological Disease
GI-530159 is a selective opener of TREK1 and TREK2 potassium channels. GI-530159 displays selectivity for TREK1/2 over TRAAK, TASK3 and other potassium channels, with an EC₅₀ of 0.76 μM for TREK1. GI-530159 reduces rat dorsal root ganglion neuron excitability and shows potential analgesic effect .

HY-12811

PF-04856264 1 Publications Verification	Sodium Channel	Neurological Disease
PF-04856264 is a potent and selective Nav1.7 inhibitor, with IC₅₀s of 28, 131, 19, and 42 nM for human, mouse, cynomolgus monkey and dog Nav1.7, respectively. PF-04856264 has low potency against the rat Nav1.7 channel. PF-04856264 shows analgesic effect .

HY-W050088

Isoxepac HP 549	Drug Derivative	Neurological Disease Inflammation/Immunology
Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

HY-109054

O-Desmethyltramadol	Drug Metabolite Opioid Receptor	Neurological Disease
O-Desmethyltramadol is the main active metabolite of tramadol (Tramadol) and can cross the blood-brain barrier. O-Desmethyltramadol mainly exerts its analgesic effect by activating the µ-opioid receptor (µ-OR) .

HY-114806

Fenclofenac Flenac; R 67408	Thyroid Hormone Receptor	Inflammation/Immunology
Fenclofenac is an orally active anti-inflammatory agent with a low ulcerogenic effect. Fenclofenac also exhibits antipyretic and analgesic activities, with an oral LD₅₀ of 2280 mg/kg in rats. Fenclofenac can be utilized in inflammation research .

HY-108519

AS1892802	ROCK	Neurological Disease
AS1892802 is a potent, orally active, and highly selective inhibitor of ROCK. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain .

HY-147907

Adenosine receptor inhibitor 1	Adenosine Receptor	Neurological Disease Inflammation/Immunology Cancer
Adenosine receptor inhibitor 1 is a potent and selective adenosine receptor (AR) inhibitor with K_i values of >1000, 68.5, >1000, >1000 nM for A₁AR, A_2AAR, A_2BAR, A₃AR, respectively. Adenosine receptor inhibitor 1 shows antinociceptive activity, anti-inflammatory effect and peripheral analgesic effect. Adenosine receptor inhibitor 1 has the potential for the research of cancer or neurodegenerative diseases .

HY-178494

Nav1.7-IN-19	Sodium Channel Potassium Channel	Neurological Disease
Nav1.7-IN-19 is a potent, selective and orally active Nav1.7 inhibitor with an IC₅₀ of 0.49 μM. Nav1.7-IN-19 shows high selectivity for Nav1.7, with selectivities of 312-fold and 662-fold against Nav1.1 and Nav1.5 in the inactivated state. Nav1.7-IN-19 exhibits weak inhibition on hERG potassium channels. Nav1.7-IN-19 exhibits analgesic effect and can be used for the research of neurological disease .

HY-P1329A

CTOP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .

HY-13222

BAN ORL 24 1 Publications Verification	Opioid Receptor	Neurological Disease Cancer
BAN ORL 24 is a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) antagonist. BAN ORL 24 has antagonistic effect for nociceptin (NOP) receptor with K_I value of 0.24 nM in CHO cell. BAN ORL 24 can be used for the research of cancer and analgesic .

HY-W013164

SC-58125	COX	Inflammation/Immunology Cancer
SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC₅₀ of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect .

HY-B0985A

Phenazopyridine 2 Publications Verification	TRP Channel	Neurological Disease
Phenazopyridine is a competitive SARM1 inhibitor, with IC₅₀ 145 μM. Phenazopyridine is a TRPM8 antagonist. Phenazopyridine has a local anesthetic/analgesic effect. Phenazopyridine is used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine can promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases .

HY-149269

COX-2-IN-30	COX Carbonic Anhydrase LOX-1	Inflammation/Immunology
COX-2-IN-30 is a benzenesulfonamide derivative, as well as an orally active and dual inhibitor of COX (IC₅₀=49 nM for COX-2, 10.4 μM for COX-1) and 5-LOX (IC₅₀=2.4 μM). COX-2-IN-30 also inhibits transmembrane hCA IX and hCA XII isoform with nanomolar calss K_i values. COX-2-IN-30 exhibits analgesic, anti-inflammatory, and ulcerogenic activities, and does not show acute gastric effect .

HY-105808

Furobufen	Drug Derivative	Neurological Disease Inflammation/Immunology
Furobufen, an anti-inflammatory agent, produces antiarthritic, antipyretic effects. Furobufen has an analgesic effect in inflamed tissue .

HY-111025

Ectylurea	Others	Neurological Disease
Ectylurea, a N-acylurea, can be used in studies of tension and anxiety symptoms, has no effect on the autonomic nervous system, and has no convulsive, analgesic or antispasmodic activity in animals .

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .

HY-108449S

Acoltremon-d3 WS-12-d₃; AR-15512-d₃; AVX-012-d₃	Isotope-Labeled Compounds TRP Channel	Neurological Disease
Acoltremon-d₃ (WS-12-d₃) is the deuterium labeled Acoltremon (HY-108449). Acoltremon is a potent and selective TRPM8 agonist, the menthol derivative, as a cooling agent. Acoltremon shows analgesic effect, and can be used in chronic neuropathic pain research .

HY-N7934

Trachelogenin (-)-Trachelogenin	HCV	Infection Neurological Disease Inflammation/Immunology
Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC₅₀ of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects .

HY-P1617

LY 190388	Endogenous Metabolite	Neurological Disease
LY 190388 is a penicillamine-containing enkefa peptide analog with μ receptor agonist activity. LY 190388 showed analgesic effect in inhibiting the writhing response in mice after intracerebroventricular administration. The analgesic effect of LY 190388 is not caused by its δ receptor agonist action, but by its μ receptor agonist activity. When LY 190388 is used together with the δ receptor antagonist ICI 174864, an additive analgesic effect is produced .

HY-136720

ZXX2-77	COX	Others
ZXX2-77 is a cyclooxygenase-1 (COX-1) selective inhibitor belonging to the benzenesulfonylanilide class of compounds. It is reported as a novel analgesic that does not cause gastric damage. ZXX2-77 has a weak analgesic effect but exhibits potent COX-1 inhibitory activity in vitro. The low oral absorption rate of ZXX2-77 leads to its weak analgesic effect in vivo. At a dose of 30 mg/kg, the maximum plasma concentration of ZXX2-77 (1.2 mM) did not reach its COX-1 IC50 value (3.2 mM). In contrast, its derivative ZXX2-79, although weaker in vitro COX inhibitory activity, is better absorbed, exhibits stronger analgesic effect and hardly causes gastric damage. These findings suggest that ZXX2-77 and its derivatives as COX-1 selective inhibitors may become effective analgesics that do not cause gastric damage.

HY-171758

BU72	Opioid Receptor	Neurological Disease
BU72 is a highly potent and long-acting agonist of μ and κ opioid receptors, and also has a partial agonist effect on δ opioid receptors (EC₅₀ values are 0.054, 0.033, and 0.58 nM, respectively). BU72 has a strong and long-lasting analgesic effect, which is mainly mediated by μ opioid receptors. BU72 has a long-lasting activity and can partially reverse the analgesic effect of morphine. BU72 can be used in the study of opioid dependence .

HY-P0007

Elcatonin Carbocalcitonin	Drug Intermediate	Metabolic Disease
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .

HY-N4219

Saikosaponin B3	Others	Neurological Disease Metabolic Disease
Saikosaponin B3 is a saikosaponin isolated from the roots of Bupleurum falcatum L., with analgesic effect. Saikosaponin B3 inhibits ACTH-induced lipolysis in the fat cells .

HY-153471

MOR agonist-1	Opioid Receptor	Infection Inflammation/Immunology
MOR agonist-1 is a MOR (μ-opioid receptor) agonist. MOR agonist-1 has good analgesic effect. MOR agonist-1 can be used for the research of pain and pain-related disorders .

HY-N11960

Ignavine	Opioid Receptor	Inflammation/Immunology
Ignavine is a conformational modulator of μ-opioid receptors (IC₅₀ = 2.0 μM). Ignavine exhibits a concentration dependent bidirectional regulatory effect in vitro. Ignavine has analgesic activity. Ignavine can be used for research on pain related conditions .

HY-173016

HINT1-IN-1	Opioid Receptor	Neurological Disease
HINT1-IN-1 (Compound 8) is the inhibitor for histidine triad nucleotide-binding protein 1 (HINT1) with a K_i of 1.14 μM. HINT1-IN-1 affects the cross-regulation between μ-opioid receptor (MOR) and NMDA receptor (NMDAR). HINT1-IN-1 enhances the analgesic effect of morphine without causing opioid tolerance and has independent analgesic effects in mouse model .

HY-159094

Nav1.8-IN-15	Sodium Channel	Neurological Disease
Nav1.8-IN-15 (compound 6) is a potent Nav1.8 inhibitor. Nav1.8-IN-15 shows analgesic effect. Nav1.8-IN-15 has the potential for the research of chronic pain .

HY-109054AS

O-Desmethyltramadol-d6 hydrochloride	Isotope-Labeled Compounds Drug Metabolite Opioid Receptor	Neurological Disease
O-Desmethyltramadol-d6 hydrochloride is a deuterated labeled O-Desmethyltramadol hydrochloride. O-Desmethyltramadol hydrochloride is the main active metabolite of tramadol (Tramadol) and can cross the blood-brain barrier. O-Desmethyltramadol hydrochloride mainly exerts its analgesic effect by activating the µ-opioid receptor (µ-OR) .

HY-P3223A

Biphalin acetate	Opioid Receptor	Neurological Disease
Biphalin acetate, a BBB-penetrable opioid peptide analog, contains two active enkephalin pharmacophores.Biphalin acetate has high affinity for opioid receptors. Biphalin acetate shows analgesic effect in acute, neuropathic, and chronic animal pain models. Biphalin acetate is also an antiviral, antiproliferative, anti-inflammatory, and neuroprotective agent .

HY-W013164R

SC-58125 (Standard)	Reference Standards COX	Inflammation/Immunology Cancer
SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect .

HY-N8290R

Lactupicrin (Standard) Lactucopicrin (Standard)	Autophagy NF-κB AMPK Reference Standards	Neurological Disease Metabolic Disease
Lactupicrin (Standard) is the analytical standard of Lactupicrin. This product is intended for research and analytical applications. Lactupicrin (Lactucopicrin) exhibits analgesic, sedative, antimalarial activities and atheroprotective effect. Lactupicrin inhibits acetylcholinesterase (AChE) with an IC₅₀ of 150.3 μM. Lactupicrin is an orally active characteristic bitter sesquiterpene lactone .

HY-P991622

MNAC13	Trk Receptor	Neurological Disease Inflammation/Immunology
MNAC13 is a kind of mouse IgG1 chimeric antibody, targeting to human TrkA. MNAC13 inhibits the NGF dependent signaling pathway by specifically binding to TrkA receptors. MNAC13 has good analgesic effect and long-lasting efficacy. MNAC13 can be used for researches on inflammatory and chronic pain .

Cat. No.	Product Name	Target	Research Area

HY-P0210

DAMGO Maximum Cited Publications 12 Publications Verification	Opioid Receptor	Cancer
DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a K_d of 3.46 nM for native μ-OPR .

HY-P1241

BAM(8-22) 1 Publications Verification	Mas-related G-protein-coupled Receptor (MRGPR)	Neurological Disease Inflammation/Immunology
BAM(8-22), a proteolytically cleaved product of proenkephalin A and sensory neuron-specific receptor (SNSR) agonist, is a potent activator of Mas-related G-protein-coupled receptors (Mrgprs), MrgprC11 and hMrgprX1. BAM(8-22) induces scratching in mice in an Mrgpr-dependent manner. In addition, BAM(8-22) has an analgesic effect and can also inhibit the activation of microglia .

HY-P3445A

Anrikefon acetate HSK21542 acetate	Opioid Receptor	Neurological Disease
Anrikefon (HSK21542) acetate is a kappa opioid receptor agonist with analgesic effect .

HY-P3445

Anrikefon HSK21542	Opioid Receptor	Neurological Disease
Anrikefon (HSK21542) is a kappa opioid receptor agonist with analgesic effect .

HY-P0210B

DAMGO TFA Maximum Cited Publications 12 Publications Verification	Opioid Receptor	Cancer
DAMGO TFA is a μ-opioid receptor (μ-OPR ) selective agonist with a K_d of 3.46 nM for native μ-OPR .

HY-P1329A

CTOP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .

HY-P3869

Lumekefamide [D-Arg2]Dermorphin-(1-4) amide	Peptides	Neurological Disease
Lumekefamide ([D-Arg2]Dermorphin-(1-4) amide) is a N-terminal shorter peptide amide of [D-Arg2]dermorphin with the hypothermic effect. Lumekefamide shows analgesic activity and degradation in soluble mouse liver and brain extracts .

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .

HY-P1617

LY 190388	Endogenous Metabolite	Neurological Disease
LY 190388 is a penicillamine-containing enkefa peptide analog with μ receptor agonist activity. LY 190388 showed analgesic effect in inhibiting the writhing response in mice after intracerebroventricular administration. The analgesic effect of LY 190388 is not caused by its δ receptor agonist action, but by its μ receptor agonist activity. When LY 190388 is used together with the δ receptor antagonist ICI 174864, an additive analgesic effect is produced .

HY-P0007

Elcatonin Carbocalcitonin	Drug Intermediate	Metabolic Disease
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .

HY-P3223A

Biphalin acetate	Opioid Receptor	Neurological Disease
Biphalin acetate, a BBB-penetrable opioid peptide analog, contains two active enkephalin pharmacophores.Biphalin acetate has high affinity for opioid receptors. Biphalin acetate shows analgesic effect in acute, neuropathic, and chronic animal pain models. Biphalin acetate is also an antiviral, antiproliferative, anti-inflammatory, and neuroprotective agent .

HY-P1078

Huwentoxin XVI	Calcium Channel	Neurological Disease
Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC₅₀ of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P1078A

Huwentoxin XVI TFA	Calcium Channel	Neurological Disease
Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC₅₀ of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P3223

Biphalin TFA	Opioid Receptor	Neurological Disease
Biphalin TFA, a BBB-penetrable opioid peptide analog, contains two active enkephalin pharmacophores. Biphalin TFA has high affinity for opioid receptors. Biphalin TFA shows analgesic effect in acute, neuropathic, and chronic animal pain models. Biphalin TFA is also an antiviral, antiproliferative, anti-inflammatory, and neuroprotective agent .

HY-P10203

μ/κ/δ opioid receptor agonist 1	Opioid Receptor	Inflammation/Immunology
μ/κ/δ opioid receptor agonist 1 is a μ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid receptor (DOR) agonist. μ/κ/δ opioid receptor agonist 1 produces a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test .

HY-P1241A

BAM(8-22) TFA	Mas-related G-protein-coupled Receptor (MRGPR)	Neurological Disease Inflammation/Immunology
BAM(8-22) TFA, a proteolytically cleaved product of proenkephalin A and sensory neuron-specific receptor (SNSR) agonist, is a potent activator of Mas-related G-protein-coupled receptors (Mrgprs), MrgprC11 and hMrgprX1. BAM(8-22) TFA induces scratching in mice in an Mrgpr-dependent manner. In addition, BAM(8-22) TFA has an analgesic effect and can also inhibit the activation of microglia .

HY-P5865

Tap1a Theraphotoxin-Tap1a; TRTX-Tap1a; µ/ω-TRTX-Tap1a	Sodium Channel	Neurological Disease
Tap1a (Theraphotoxin-Tap1a) is a spider venom peptide that inhibits sodium channels with IC₅₀s of 80 nM and 301 nM against Na_v1.7 and Na_v1.1, respectively. Tap1a shows analgesic effects .

HY-P11480

TrkA/NGF-IN-1	Trk Receptor	Neurological Disease
TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC₅₀: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .

HY-P3549

[D-Ala2] Leu-Enkephalinamide	Peptides	Neurological Disease
[D-Ala2] Leu-Enkephalinamide is an enkephalin analog. [D-Ala2] Leu-Enkephalinamide has great corneal permeability and analgesic effect. [D-Ala2] Leu-Enkephalinamide can be used for the research of ocular diseases .

HY-P3869A

Lumekefamide TFA [D-Arg2]Dermorphin-(1-4) amide TFA	Peptides	Neurological Disease
Lumekefamide TFA ([D-Arg2]Dermorphin-(1-4) amide TFA) is a N-terminal shorter peptide amide of [D-Arg2]dermorphin with the hypothermic effect. Lumekefamide shows analgesic activity and degradation in soluble mouse liver and brain extracts .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991622

MNAC13	Trk Receptor	Neurological Disease Inflammation/Immunology
MNAC13 is a kind of mouse IgG1 chimeric antibody, targeting to human TrkA. MNAC13 inhibits the NGF dependent signaling pathway by specifically binding to TrkA receptors. MNAC13 has good analgesic effect and long-lasting efficacy. MNAC13 can be used for researches on inflammatory and chronic pain .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-101392

Harmane 1 Publications Verification	Alkaloids other families Pyridine Alkaloids Plants Indole Alkaloids Source Classification	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor
Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-N3017

Artemitin 1 Publications Verification	Flavonols Monophenols Flavonoids other families Classification of Application Fields Phenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Antibiotic
Artemitin is a flavonoid neuroanesthetic agent with moderate cytotoxicity. Artemitint has selective inhibitory activity against Meth-A sarcoma cells with an ED₅₀ of 5-10 μg/mL, and has no significant effect on LLC lung cancer cells. Artemitin exerts anticancer activity by affecting cell proliferation signaling pathways, and also has potential anti-inflammatory and neuroprotective effects. Artemitin exhibits a dose-dependent antinociceptive effect in the mouse hot plate test, with an ED₅₀ of 1.6 μg/kg, and has analgesic activity .

HY-N8290

Lactupicrin Lactucopicrin	Monophenols Terpenoids Genista quadriflora Munby Sesquiterpenes Phenols Plants Compositae Source Classification	LOX-1 NF-κB Cholinesterase (ChE) Parasite
Lactupicrin (Lactucopicrin) exhibits analgesic, sedative, antimalarial activities and atheroprotective effect. Lactupicrin inhibits acetylcholinesterase (AChE) with an IC₅₀ of 150.3 μM. Lactupicrin is an orally active characteristic bitter sesquiterpene lactone .

HY-N8487

7-Methoxyflavone	Flavonoids Neurological Disease Classification of Application Fields Flavones Leguminosae Zornia brasiliensis Plants Inflammation/Immunology Disease Research Fields Source Classification	Cytochrome P450
7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .

HY-111664

(R)-(+)-Citronellal (+)-Citronellal	Structural Classification Other Monoterpenes Classification of Application Fields Terpenoids Citrus limon (L.) Burm. F. Rutaceae Metabolic Disease Plants Endogenous metabolite Disease Research Fields Citrus reticulata Blanco Source Classification	Bacterial Fungal Insecticide Taste Receptor Opioid Receptor
(R)-(+)-Citronellal ((+)-Citronellal) is a monoterpenoid compound and is one of the main components of essential oils from plants such as lemon grass. (R)-(+)-Citronellal has antibacterial, antifungal, and insecticidal activities. (R)-(+)-Citronellal alleviates the bitterness of caffeine by antagonizing the bitter taste receptors Tas2r43 (IC₅₀ = 84 μM) and Tas2R46. (R)-(+)-Citronellal generates analgesic activity by activating the opioid receptor (broad-spectrum opioid receptor) pathway, and its effect is particularly significant for inflammatory pain .

HY-N0398

Sec-O-Glucosylhamaudol	Flavonoids Flavones Carpesium cernuum L. Umbelliferae Plants	Opioid Receptor
Sec-O-Glucosylhamaudol is a natural compound extracted from Peucedanum japonicum Thunb, decreases levels of μ-opioid receptor, with analgesic effect .

HY-101392A

Harmane hydrochloride 1 Publications Verification	Apocynaceae Alkaloids Other Alkaloids Plants Rauwolfia canescens Source Classification	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor
Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-N0885

Telocinobufagin 1 Publications Verification Telobufotoxin; Telocinobufogenin	Structural Classification Animals Classification of Application Fields Other Diseases Disease Research Fields Steroids Source Classification	JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na ⁺/K ⁺-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .

HY-145491

Resolvin D5	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	ERK NF-κB CCR
Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatory T cell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis .

HY-N4267

Yangambin	Cardiovascular Disease Structural Classification other families Classification of Application Fields Lignans Phenylpropanoids Plants Disease Research Fields Source Classification	Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human UGT1A1, and an IC₅₀ of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB₄-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca ²⁺ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .

HY-N7934

Trachelogenin (-)-Trachelogenin	Infection Monophenols Classification of Application Fields Lignans Phenols Rhaponticum carthamoides (Willd.) Iljin Phenylpropanoids Plants Compositae Disease Research Fields Inflammation/Immunology Source Classification	HCV
Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC₅₀ of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects .

HY-N0346

4-Methoxycinnamic acid ethyl ester Ethyl p-methoxycinnamate	Structural Classification Kaempferia galanga L. Iridoids Terpenoids Plants Source Classification Zingiberaceae	COX NF-κB TNF Receptor Interleukin Related Apoptosis VEGFR Bacterial Dengue Virus Caspase
4-Methoxycinnamic acid ethyl ester (Ethyl p-methoxycinnamate) is an orally active natural compound found. 4-Methoxycinnamic acid ethyl ester exerts anti-inflammatory effects by inhibiting cyclooxygenase (COX-1 (IC₅₀ = 1.12 μM) and COX-2 (IC₅₀ = 0.83 μM)), NF-κB (IC₅₀ = 88.7 μM) and cytokine production (TNF-α (IC₅₀ = 96.84 μg/mL) and IL-1β (IC₅₀ = 166.4 μg/mL)). 4-Methoxycinnamic acid ethyl ester inhibits tumor cell proliferation, migration and cancer metabolism and induces apoptosis.4-Methoxycinnamic acid ethyl ester inhibits VEGF expression, thereby inhibiting angiogenesis. 4-Methoxycinnamic acid ethyl ester has a significant inhibitory effect on dengue virus and Mycobacterium tuberculosis. 4-Methoxycinnamic acid ethyl ester has analgesic effects in rats .

HY-N4219

Saikosaponin B3	Triterpenes Terpenoids Plants Umbelliferae Source Classification Carphephorus corymbosus (Nutt.) Torr. & A.Gray	Others
Saikosaponin B3 is a saikosaponin isolated from the roots of Bupleurum falcatum L., with analgesic effect. Saikosaponin B3 inhibits ACTH-induced lipolysis in the fat cells .

HY-N11960

Ignavine	Structural Classification Alkaloids Aconitum tasiromontanum Nakai Other Alkaloids Ranunculaceae Plants Source Classification	Opioid Receptor
Ignavine is a conformational modulator of μ-opioid receptors (IC₅₀ = 2.0 μM). Ignavine exhibits a concentration dependent bidirectional regulatory effect in vitro. Ignavine has analgesic activity. Ignavine can be used for research on pain related conditions .

HY-N8290R

Lactupicrin (Standard) Lactucopicrin (Standard)	Structural Classification Monophenols Terpenoids Genista quadriflora Munby Sesquiterpenes Phenols Plants Compositae Source Classification	Autophagy NF-κB AMPK Reference Standards
Lactupicrin (Standard) is the analytical standard of Lactupicrin. This product is intended for research and analytical applications. Lactupicrin (Lactucopicrin) exhibits analgesic, sedative, antimalarial activities and atheroprotective effect. Lactupicrin inhibits acetylcholinesterase (AChE) with an IC₅₀ of 150.3 μM. Lactupicrin is an orally active characteristic bitter sesquiterpene lactone .

HY-N0398R

Sec-O-Glucosylhamaudol (Standard)	Structural Classification Flavonoids Flavones Carpesium cernuum L. Umbelliferae Plants	Reference Standards Opioid Receptor
Sec-O-Glucosylhamaudol (Standard) is the analytical standard of Sec-O-Glucosylhamaudol. This product is intended for research and analytical applications. Sec-O-Glucosylhamaudol is a natural compound extracted from Peucedanum japonicum Thunb, decreases levels of μ-opioid receptor, with analgesic effect .

HY-N16538

4-(Acetoxymethyl)phenyl glucoside	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source Classification	Drug Derivative
4-(Acetoxymethyl)phenyl glucoside is a type of gastrodin derivative that can cross the blood-brain barrier. 4-(Acetoxymethyl)phenyl glucoside exhibits sedative, anticonvulsant and analgesic effects in mouse models. 4-(Acetoxymethyl)phenyl glucoside can be used for research on senile cardiovascular and cerebrovascular diseases as well as brain nerve disorders .

HY-N8487R

7-Methoxyflavone (Standard)	Flavonoids Flavones Leguminosae Zornia brasiliensis Plants Source Classification	Reference Standards Cytochrome P450
7-Methoxyflavone (Standard) is the analytical standard of 7-Methoxyflavone (HY-N8487). This product is intended for research and analytical applications. 7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .

HY-N18124

1-O-Tigloyl-1-O-debenzoylohchinal	Structural Classification Melia azedarach Linn. Ketones, Aldehydes, Acids Plants Meliaceae Source Classification	Others
1-O-Tigloyl-1-O-debenzoylohchinal is an orally active limonoid-type triterpenoid anti-inflammatory and peripheral analgesic agent isolated from the fruits of Melia toosendan. 1-O-Tigloyl-1-O-debenzoylohchinal significantly inhibits acetic acid (HY-Y0319)-induced increase in vascular permeability, λ-Carrageenan (HY-N9470)-induced paw edema, and acetic acid-induced writhing response in mice. 1-O-Tigloyl-1-O-debenzoylohchinal shows no significant analgesic effect in the hot-plate test, and acts mainly on the peripheral rather than the central nervous system. 1-O-Tigloyl-1-O-debenzoylohchinal can be widely used in the research of acute or chronic inflammation, stomachache and other related diseases .

Cat. No.	Product Name	Chemical Structure

HY-B0527AS

Amitriptyline-d6 hydrochloride

Amitriptyline-d₆ hydrochloride is the deuterium labeled Amitriptyline hydrochloride (HY-B0527A). Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (K_i = 3.45 nM) and NET (K_i = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to DAT (with K_i = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (K_i = 11-24 nM), H1 receptors (K_i = 0.5-1.1 nM), adrenergic α1 receptors (K_i = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC₅₀ = 4.78 μM) and it has cardiotoxicity.

HY-108449S

Acoltremon-d3
Acoltremon-d₃ (WS-12-d₃) is the deuterium labeled Acoltremon (HY-108449). Acoltremon is a potent and selective TRPM8 agonist, the menthol derivative, as a cooling agent. Acoltremon shows analgesic effect, and can be used in chronic neuropathic pain research .

HY-109054AS

O-Desmethyltramadol-d6 hydrochloride
O-Desmethyltramadol-d6 hydrochloride is a deuterated labeled O-Desmethyltramadol hydrochloride. O-Desmethyltramadol hydrochloride is the main active metabolite of tramadol (Tramadol) and can cross the blood-brain barrier. O-Desmethyltramadol hydrochloride mainly exerts its analgesic effect by activating the µ-opioid receptor (µ-OR) .

HY-132428S

O-Desmethyl Tramadol-d6
O-Desmethyl Tramadol-d₆ is the deuterium labeled O-Desmethyl Tramadol. O-Desmethyl Tramadol is a primary active metabolite of Tramadol. O-Desmethyl Tramadol is mainly responsible for its μ-opioid receptor-related analgesic effect. Tramadol is metabolized to O-Demethyltramadol mainly by the cytochrome P450 (CYP) 2D6 enzyme .

HY-W050088S

Isoxepac-d6

Isoxepac-d₆ (HP 549-d₆) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

HY-B0363S

Nimesulide-d5
Nimesulide-d₅ is a deuterium labeled Nimesulide. Nimesulide is a selective COX-2 inhibitor, with IC₅₀s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC₅₀ >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties .

HY-B0363S1

Nimesulide-13C6
Nimesulide- ¹³C₆ (R805- ¹³C₆) is ¹³C labeled Nimesulide. Nimesulide is a selective COX-2 inhibitor, with IC₅₀s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC₅₀ >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.

HY-W777360

Harman-13C2,15N

Harman- ¹³C₂, ¹⁵N is ¹³C and ¹⁵N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-W700834

Harman-d3

Harman-d₃ is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

Cat. No.	Product Name		Classification

HY-159562

COX-2-IN-46		Azide
COX-2-IN-46 (compound 5m) is an anti-inflammatory agent with potent analgesic activity. COX-2-IN-46 exhibits a significant inhibitory effect on COX-2 (IC₅₀=87.74 nM) .

HY-159561

COX-1-IN-2		Azide
COX-1-IN-2 (compound 5h) is an anti-inflammatory agent with potent analgesic activity. COX-1-IN-2 exhibits a significant inhibitory effect on COX-1 (IC₅₀=38.76 nM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks